2157 logo

Lepu Biopharma SHSC:2157 Stock Report

Last Price

HK$2.65

Market Cap

HK$4.5b

7D

0%

1Y

-24.7%

Updated

23 Dec, 2024

Data

Company Financials +

Lepu Biopharma Co., Ltd.

SHSC:2157 Stock Report

Market Cap: HK$4.5b

2157 Stock Overview

A biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. More details

2157 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Lepu Biopharma Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lepu Biopharma
Historical stock prices
Current Share PriceHK$2.65
52 Week HighHK$6.50
52 Week LowHK$2.16
Beta-0.24
1 Month Change-5.69%
3 Month Change-10.17%
1 Year Change-24.72%
3 Year Changen/a
5 Year Changen/a
Change since IPO-54.31%

Recent News & Updates

Recent updates

Shareholder Returns

2157HK BiotechsHK Market
7D0%-3.9%-0.5%
1Y-24.7%-5.7%19.9%

Return vs Industry: 2157 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.

Return vs Market: 2157 underperformed the Hong Kong Market which returned 19.9% over the past year.

Price Volatility

Is 2157's price volatile compared to industry and market?
2157 volatility
2157 Average Weekly Movement12.4%
Biotechs Industry Average Movement11.1%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.6%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 2157 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2157's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018491Ziye Suiwww.lepubiopharma.com

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive.

Lepu Biopharma Co., Ltd. Fundamentals Summary

How do Lepu Biopharma's earnings and revenue compare to its market cap?
2157 fundamental statistics
Market capHK$4.53b
Earnings (TTM)-HK$77.30m
Revenue (TTM)HK$218.29m

20.8x

P/S Ratio

-58.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2157 income statement (TTM)
RevenueCN¥205.08m
Cost of RevenueCN¥43.56m
Gross ProfitCN¥161.52m
Other ExpensesCN¥234.14m
Earnings-CN¥72.62m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.042
Gross Margin78.76%
Net Profit Margin-35.41%
Debt/Equity Ratio80.9%

How did 2157 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 23:30
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lepu Biopharma Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sean WuMorgan Stanley
Jack LinMorgan Stanley